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v Laboratory animals have long been used as surrogates for human beings, because it has 
been considered acceptable to expose them to conditions and procedures which would not 
be considered acceptable, if applied to ourselves. 
 Initially, the focus was mainly on gaining a better understanding of how the body’s 
cells, organs, and systems function and are controlled, and how failures of one kind or 
another can lead to pathological conditions. Then, from about the middle of the last cen-
tury, animals came to be used more and more in tests to determine the effects of exposure 
to chemicals and chemical products—in attempts to determine information of direct rele-
vance concerning the effi cacy of drugs and vaccines and/or the adverse effects of chemicals 
and other kinds of chemical products, in the hope of predicting likely effects in humans, as 
a basis for appropriate risk assessment and risk management. 
 However, attitudes toward the reliance on this approach are now changing, with the 
increasing recognition that the knowledge gained from animal studies cannot be expected 
to have direct relevance to humans, but can even have dangerous consequences. 
 This problem is particularly acute for the pharmaceutical industry, which is in a state of 
crisis because of the increasing occurrence of the late withdrawal of new drugs as a result of 
lack of effi cacy or unacceptable side effects not detected during preclinical testing, despite 
the application of highly expensive and seemingly sophisticated testing in animals. 
Meanwhile, the introduction of the EU REACH system for chemical toxicity has revealed 
that many more chemicals than had been expected lack the information needed to provide 
for what is considered to be an acceptable risk assessment. Also, it has to be recognized, 
albeit very reluctantly in some quarters, that two of the main types of animal test, which are 
very costly and which can cause great suffering to the animals involved, namely, reproduc-
tive toxicity tests and the rodent bioassay for chemical carcinogens, simply cannot be relied 
on to identify chemicals likely to have adverse effects during human reproduction or to 
cause cancer in humans. I have never understood how the full lifetime feeding of the maxi-
mum tolerated dose of a chemical to a rat or mouse could tell us anything about the carci-
nogenicity of the chemical for rodents, let alone for humans. We don’t eat very high doses 
of single chemicals throughout our lives. 
 There are two main and insuperable reasons for these diffi culties. First, functions and 
controls in animals and humans tend to be very different in detail, however similar they may 
appear to be on the surface. Animals are highly adapted to their individual and specifi c life-
styles and environments. During evolution, species separate and diverge from common 
ancestors, based on these adaptations, which tend not to involve the emergence of some-
thing totally new, but which rely instead on modifi cations of what was already there. This 
has profound implications for attempts to model human diseases in animals, especially 
since, in view of the absence of suffi cient knowledge about what is being modeled, it is 
impossible to judge whether or not a particular model has any value. 
 Russell and Burch referred to the problem of species difference in  The Principles of 
Humane Experimental Technique (1959), when they warned of the “high fi delity fallacy.” 
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This is the assumption that, because other mammals are similar to humans in many respects, 
they are always the best models to use in fundamental biomedical research, drug develop-
ment, and toxicity testing, where humans are the focus of concern. This warning has been 
largely ignored. 
 One response to the unsolvable problem of species differences is the attempt to human-
ize animals by transferring human genes into their genomes, in the hope of simulating 
effects and responses in humans. However, that can be considered naïve, since the manipu-
lation of complex networks of interacting controls, which are not suffi ciently well under-
stood and which will inevitably differ considerably in animals and humans, is likely to 
produce information which cannot be interpreted with confi dence, and which may be dan-
gerously misleading. 
 The second insuperable problem is that the “human” being to be modeled in animals 
doesn’t actually exist. Human polymorphism leads to an infi nite variety of different 
humans—there are many, many subpopulations within the overall human population, 
which will differ in their susceptibilities to disease and in their responses to chemicals and 
chemical products, including drugs. One result of this is that a drug which is highly effec-
tive in one patient can be lethal to another. Similarly, a chemical which has no effect in some 
individuals can induce a highly allergic response in others. 
 The only way forward is to recognize that the modern, but still developing, techniques 
of cell biology and molecular biology, combined intelligently with the vast information 
storage and computational systems which are now available, should be applied directly to 
human material in vitro and ex vivo, and in some situations, subject to strict ethical con-
trols, to human volunteers. Carefully planned and executed, this approach could take 
account of human polymorphism, past or concurrent disease, and the differential effects of 
age, occupation, lifestyle, and exposure to medicines and other chemicals. 
 In the pharmaceutical industry, for example, the “one drug suits all” concept has been 
overthrown, and therapies in the future will involve “personalized medication,” where the 
treatment will be designed specifi cally for the individual patient. In the case of other chemi-
cals and products, the “one test suits all” concept also needs to be abandoned, in terms of 
both effects and people, and replaced by “personalized safety evaluation,” which takes 
account of hereditary and lifestyle factors. 
 The very challenging prospect, which is the subject of this most important book, is that 
human-based in vitro studies and procedures could make major contributions to the two 
seemingly insuperable problems, if handled critically and intelligently. The increasing array 
of in vitro systems includes the use of cell fractions, cell lines, stem cells (including induced 
pluripotent stem cells), engineered tissues, dynamic bioreactors, multiorgan systems, and 
cells-, organs-, and (even) humans-on-a-chip, combined with high-throughput screening, 
high-content screening, the “omics” approaches, systems modeling and simulation, phar-
macokinetic and toxicokinetic modeling, virtual tissue modeling, virtual human popula-
tions, and biomarkers, strategically used, with effective bioinformatics support. 
 One problem, evident from the chapters in this book, is the vastness of the range of 
technical possibilities. Manageability will be a key factor in the way forward, combined with 
the need to rigorously and regularly evaluate the relevance and reliability of what is proposed 
or what is being done, including whether it will yield a clear and applicable outcome. 
 One trap which must be avoided is to use animal test data as the “gold standard” to be 
matched by nonanimal, replacement alternative tests. If the animal tests themselves are not 
suffi ciently relevant and reliable, how can the data they provide be used in the validation of 
human-based (by defi nition, more relevant) tests? Sadly, this trap is often laid, not least by 
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some regulators, who say that they feel “more comfortable” with animal test data than with 
predictions based on in vitro procedures. 
 It is essential that the highest scientifi c standards should be made, through, for exam-
ple, compliance with the principles of Good Cell Culture Practice, which is analogous to 
Good Laboratory Practice and Good Manufacturing Practice. 
 There is also a danger of overspecialization and isolation, leading to blind alleys and 
the pursuit of red herrings, and of the production of enormous amounts of data. Russell 
and Burch referred to this in  The Principles , where they feared the “gradual growth of awe 
before experts,” and said that “respect for expert specialist knowledge should never 
become uncritical.” They added that “the problem of interspecialist communication 
merges into the general one of information retrieval” and that “we now have far too much 
information as a species to digest as individuals.” What they foresaw is an even greater 
problem today, when we are overwhelmed with information which is not critically evalu-
ated before it is dumped on the world. We even have electronic journals, which publish 
manuscripts as they are received, without independent peer review. What we need are 
more avowed synthesizers, capable of broad and lateral thinking, and not committed to a 
particular dogma or strategy. 
 In particular, there is a need to recognize that it is not possible to have “mechanistic 
tests” without suffi cient knowledge of the “mechanism” on which the test purports to be 
based. That is why fundamental and applied toxicology must progress hand-in-hand, so 
that there is greater confi dence that the right questions are being asked, before attempts are 
made to answer them. 
 It is also essential to make full use of bioinformatics and what is known as systems toxi-
cology and evidence-based toxicology, as a way of developing and applying intelligent and 
integrated strategies involving stepwise approaches. One major concern is that the nonani-
mal test possibilities will become so numerous and so costly that their use will not be prac-
ticable. Decision-tree schemes will therefore be essential. For example, if the likelihood of 
major hepatotoxicity is revealed, it will not be essential to test for toxicity to the kidney or 
the thyroid gland, or for carcinogenicity or reproductive toxicity. 
 It is now almost exactly 50 years since I went as a postdoctoral fellow learn about cell 
culture in Harry Rubin’s group in the Virus Laboratory at the University of California at 
Berkeley. The use of cell cultures had created the breakthroughs in quantitative animal 
virology, which led,  inter alia , to the production of polio vaccines (albeit at the cost of the 
lives of hundreds of thousands of rhesus monkeys, whose kidney cells were used to pro-
duce the viruses for the vaccines). We worked on Rous sarcoma virus (RSV) and chicken 
leucosis viruses in chick embryo fi broblast cell cultures. Rubin and Temin had developed 
an assay for RSV, based on the production of foci of virus-transformed fi broblasts, and 
Temin did the crucial experiments which showed that RSV, an RNA virus, made a DNA 
copy of itself, which was used to produce new virus particles. The enzyme involved was 
reverse transcriptase, and its discovery was one of the most important leaps forward in cell 
and molecular biology. 
 At that time, the fi broblasts and kidney cells were mere substrates in which the viruses 
could replicate, and there were few signs of the outstanding and astounding developments 
in cell culture technology which would give us the impressive range of techniques and 
procedures which are available today. It could be said that the fundamental science of toxi-
cology in general, and the applied science of toxicity testing in particular, have been pain-
fully slow in adopting these developments to their benefi t, largely due, no doubt, to the 
 entrenchment of the animal experimentation bias. However, I am confi dent that the 
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regrettable situation is about to change, thanks to the huge efforts being invested in 
industry and in academia throughout the world. 
 I am greatly encouraged by the excellent chapters in this book. However, as Russell and 
Burch warned, there is a danger that the reader will be overwhelmed by the detail and the 
sophistication. One way to overcome that problem is to begin by reading only the 
Introductions of the various chapters, to see how well the authors have set the background 
scene of what is to come, before looking at their Discussions and Conclusions sections, to 
see how they summarize the current state of the art and look to the future. Then, an overall 
impression having been gained, the detailed coverage and supportive evidence in the mid-
dle of each chapter can be carefully scrutinized and appreciated. 
 Ultimately, the question is whether the various in vitro approaches will contribute to an 
increase in understanding and a decrease in uncertainty. We cannot escape the fact that, 
although we may have many pieces of information to try to fi t together, we certainly don’t 
have all the pieces we need and we don’t know how many pieces are missing. In addition, 
we must be suspicious that the pieces we do have are not merely the parts of one puzzle, 
but may be parts of an unknown number of different puzzles. Moreover, we cannot assume 
that all the pieces are of equal value, as we know that, far from being lifeless equivalents cut 
from the original picture with a jigsaw to form a conventional jigsaw puzzle, there are, 
within each piece of information having potential pharmacotoxicological signifi cance, sto-
ries and histories, and pluses and minuses, and main streams and blind alleys, and dynamic 
interactions among them that are far more profound. Worst of all, we have no picture on a 
box to guide us—we have to create the eventual picture or pictures ourselves, by using 
strategies and applying rules which we have to devise and validate along the way. 
 Nottingham, UK Michael Balls 
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 In this book, we attempt to bring together the important issues and considerations we 
believe are needed in order to develop a workable, reliable, integrated testing strategy for 
the replacement of animals in toxicity testing regimes. 
 We begin the book with a review on “The past, present, and future of chemical risk 
assessment” by Alice Limonciel. She describes the history of the development of chemical 
testing and the evolution of chemical regulation. This process has had several key mile-
stones. Among them were Elixir Sulfanilamide in 1937 and the thalidomide disaster in the 
late 1950s and early 1960s. The unfortunate use of the solvent diethylene glycol in Elixir 
Sulfanilamide caused the deaths of over a hundred people due to acute renal failure and 
introduced regulations where proof of safety of a compound was required to be shown 
before marketing. The thalidomide disaster introduced the necessity to test for reproduc-
tive toxicity. It is perhaps not surprising that these two examples were pharmaceuticals. 
 While testing is important for the chemical and cosmetic industry, the pharmaceutical 
industry is somewhat a special case as compounds are designed to be taken up, distributed, 
and have biological activity. Thus testing is a necessary and highly regulated part of drug 
development. However, just because we rigorously test compounds doesn’t mean we nec-
essarily predict toxicities or a lack of them in humans. Individually, nonhuman mammals 
poorly predict human toxicity, and thus several species are used to cover predictive ground, 
unfortunately at the expense of specifi city. Therefore, there is an inevitable loss of com-
pounds which are toxic in animals but safe in humans. Thomas Hartung (contributor of 
Chap.  11 ) has pointed out that aspirin, one of the most widely used pharmaceuticals today, 
would have most likely not been brought to market if it had to pass through current pre-
clinical testing regimes. Thus one of the main scientifi c rationales for developing in vitro 
alternatives is to improve on current animal-based testing regimes in the preclinical phase. 
 The ability to maintain cells outside the living body is documented as far back as 1885, 
when the zoologist Wilhelm Roux maintained embryonic chicken cells in a warm saline 
solution for several days. However, the true foundation of modern cell culture was arguably 
not until the mid 1950s when Eagle began to investigate the nutritional requirements of 
cells in culture [1, 2]. Already in 1959, Russell and Burch had realized the importance of 
cell culture as a real alternative to animal use, stating that “Mammalian tissue cultures have 
become one of the most important replacement techniques, and indeed one of the most 
important developments in biology” [3]. Since 1959, there has been a dramatic increase in 
the development and use of in vitro cell cultures which was mostly driven by technological 
advances in molecular biology such as polymerase chain reaction (PCR), transfection, and 
gene silencing. Primary cells and cell lines have now become extremely widely used tools. 
The improvements in cell immortalizations, such as telomerase overexpression [4], the 
development of high-content omic approaches, and the discovery of methods to make 
somatic cells pluripotent are continuing to push back the borders of in vitro research. These 
approaches are well suited to pharmacological and toxicological approaches and have great 
potential to increase our understanding of the molecular perturbations of chemicals and 
may eventually overtake animal studies as predictive tools. 
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exposure. Thus for the pharmaceutical industry in particular, where the chemical is intended 
to enter the body and usually the circulation, all cells are potentially exposed making hazard 
identifi cation of primary importance. If in vitro toxicity testing regimes are to replace whole 
animal tests for pharmaceutical development, they will have to represent all the major organs 
and tissues. While this might sound an impossible task, it could be more manageable by 
considering a tiered approach using the most commonly affected cells or tissues fi rst. The 
fi rst line are the liver and kidney, since, due to their respective roles in xenobiotic metabolism 
and excretion, they are exposed to and interact with a wide variety of chemical entities. So 
theoretically if a lead chemical demonstrated either hepatotoxicity or nephrotoxicity at con-
centrations close to their therapeutic range, they should be stopped at this stage. However, 
if this is not the case, other cell systems would then need to be tested. In vitro models for 
liver and kidney toxicity are discussed in Chaps.  2 and  4 , respectively. The heart is obviously 
a vital organ and any compound that adversely affects its function could have very serious 
implications for health. Cardiotoxicity is the primary reason for postmarketing drug with-
drawals and thus is of major interest for drug development [5]. The progress in the develop-
ment of in vitro cardiac models is discussed in Chap.  3 , and detailed protocols are provided. 
Neurotoxicity and injury to the blood brain barrier are also a major toxicological concern, 
particularly with the potential of chemical-induced injury to contribute to neurodegenera-
tive diseases such as Alzheimer’s and Parkinson’s. The issues concerned and in vitro models 
available are detailed in Chaps.  6 and  7 . The lung due to its involvement in blood oxygen-
ation, metabolism, and the elimination of volatile substances is also an important toxicologi-
cal target and is of special interest for drug delivery. The lung represents a selective barrier 
between the external and internal environments and is thus challenged on a permanent basis 
with air-borne pollutants including nanoparticles. In vitro models of the lung are reviewed 
in Chap.  5 , while the special consideration of nanoparticles is addressed in Chap.  21 . 
Xenobiotics have the potential to interfere with immune responses either by increasing or 
decreasing specifi c immune activity, and thus can lead to immunosuppression, sensitization, 
autoimmune disease, and may even promote cancer. The challenges associated with the 
development of immunotoxicity assays in vitro are discussed in Chap.  11 . 
 The organs and tissues mentioned so far are important as their disturbance can lead to 
severe ill health and mortality. However, nonvital organs where quality of life can be severely 
impaired should also be considered for in vitro screening regimes. For example, many com-
pounds, including aminoglycoside antibiotics, can cause permanent deafness, a situation 
which can have serious implications to life quality. The mechanism of ototoxicity and the in 
vitro models available are discussed in Chap.  9 . Of special consideration for the cosmetic 
industry are the external physiological barriers and body surfaces, where cosmetics are often 
applied, for example the skin and eyes. Indeed the progress for the development of alterna-
tive nonanimal strategies has been most successful, so far, for dermal and ocular toxicity 
(Chaps.  8 and  10 ). 
 Many compounds either through direct action on DNA or indirect action, for example 
through chronic tissue injury, immunomodulation, and endocrine disruption, can cause 
cellular and tissue perturbations leading to the development of cancer. Thus, the carcino-
genic potential of compounds is of critical importance for human safety. While several in 
vitro systems for testing genotoxicity are available, the identifi cation of nongenotoxic car-
cinogens is more diffi cult. These issues are elaborated in more detail in Chap.  14 . 
 In addition to effects of compounds on the intended individual, we also need to con-
sider their impact on fetal development and reproductive potential. We now know that the 
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placenta is not an all exclusive barrier to the maternal environment. Certain chemicals, for 
example thalidomide, can cross this barrier, where they may cause serious adverse develop-
mental effects. Chemicals, such as endocrine disrupters, may in addition reduce fertility 
which is a serious societal concern. Thus development and reproductive toxicity are impor-
tant endpoints and are discussed in Chaps.  12 and  13 . 
 As already mentioned, the fairly recent discovery of the possibility to induce pluripo-
tency in somatic human cells (inducible Pluripotent Stem Cells, iPSC) [6], has the potential 
to revolutionize how we study human diseases and is likely to provide a plethora of new 
biological tools for pharmacological and toxicological investigations. Apart from providing 
a new source for primary cell culture, iPSC-derived target cells could form the fi rst in vitro 
basis for studying population-based dynamics, genetic susceptibility, and idiosyncrasies. 
The development and use of iPSC for the major target organs is addressed in Chap.  15 , 
while the use of iPSC and progenitor cells for neurodevelopmental toxicity is specifi cally 
reviewed in Chap.  16 . 
 One of the major driving forces for the use of in vitro systems is their applicability to 
high-content analysis. Indeed the coupling of well-characterized relevant cell culture sys-
tems with powerful high-content, information-rich techniques such as transcriptomics, 
proteomics, metabolomics, and high-content imaging is pushing back the boundaries and 
allowing a true mechanistic understanding of molecular events (Chaps.  17 and  18 ) [7]. The 
use of these new technologies has provided us with a vast amount of mechanistic informa-
tion on how cells function at a molecular level and how they deal with chemical and physi-
ological stressors [8]. These types of experimental approaches are driving a new age in 
toxicological science where the focus is the discovery and elucidation of molecular mecha-
nisms underlying chemical-induced cellular perturbations (Chap.  19 ). Indeed the OECD is 
promoting the development of the so-called “Adverse Outcome Pathways” (AOP) concept 
where a molecular initiating event, in which a chemical interacts with a biological target(s), 
is followed by a sequential series of events that ultimately result in an adverse outcome in 
an individual organisms or a population [9]. The elucidation of such molecular pathways 
relevant for adverse effects of compounds can lead us to the discovery of mechanistically 
anchored biomarkers. These biomarkers can be used to develop better predictive systems or 
may even be employed in clinical settings (Chap.  20 ). 
 A very important but often neglected aspect of in vitro toxicology is pharmacokinetics 
or toxicokinetics. Kinetics deals with how a test compound is altered by the system it is 
applied to. For an in vitro system, the available concentration of the compound can be 
decreased by binding to cell culture-ware such as a plastic cell culture dish, by binding to 
proteins in the cell culture medium, by evaporation and due to cellular uptake or cellular 
metabolism. The latter two points are critical in both in vitro and in vivo systems and are 
discussed in detail in Chap.  22 . Knowing the actual concentration that cells can interact 
with, either by measurement as a free concentration in the cell medium or as a tissue con-
centration in the cell lysate, is crucial not only for experimental interpretation but also to 
extrapolate to the in vivo situation. Indeed, we must eventually extrapolate from in vitro to 
in vivo in order to establish safe exposure limits, which is after all the end goal of the exer-
cise. These issues are dealt with in Chaps.  23 and  24 . 
 In order to realize the vision of Russell and Burch and to go a step closer to animal free 
testing, we will require an integrated, systems biology approach, utilizing good cell culture 
practice [10], good laboratory practice, relevant and robust biological systems together 
with appropriate analytical tools and prediction models. Such an integrated strategy should 
be fi t-for-purpose and need to be recognized and accepted by regulatory authorities. Thus 
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it is of utmost importance that scientists, industry, and regulators understand the needs of 
each other; only then can an integrated, tiered strategy based on in vitro techniques be put 
in place. In Chap.  25 , the considerations in the development of in vitro toxicity testing 
methods intended for regulatory use are detailed. 
 In conclusion, the majority of the contributors of this book share our opinion that the 
use of animals for safety assessments is approaching its end of life and will eventually be 
phased out by more predictive human-derived in vitro systems and  in silico approaches. 
What these in vitro systems will be like is uncertain, but we would be surprised if iPSCs 
were not an integral part of it, as this technology allows both human population- based 
screening and safety evaluation tailored to individuals. Finally, we were delighted to receive 
such a positive response from the experts we contacted and were very pleased that, without 
exception, each chapter was written with the high standards and expert insight that we 
hoped for. We are confi dent that this book has accomplished its goals and will be of benefi t 
not only to students, scientists, and regulators working in the fi eld of chemical safety assess-
ment but also to the wider scientifi c audience. 
 Ispra (VA), Italy Anna Bal-Price 
 Innsbruck, Austria Paul Jennings 
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